EVALUATING OPTIMAL PRODUCT MIX USING DYNAMIC SIMULATION: A TOMATO PROCESSING CASE

Technology-driven change is everywhere and value-capture from new technology is challenging for business managers. Also rival firms may use technology as part of major success strategies. This situation leads managers to be keenly interested in evaluation of alternative technologies prior to making a sunk investment in physical facilities. In contemplating new or added-capacity processing facilities, managers and investors must evaluate return on investment (ROI). Evaluation of ROI is complex because it varies by alternative technology and the resultant potential product mix alternatives associated with that technology at the time the investment capital is committed to build the processing plant. This research examines optimal alternative product mix from a processing plant technology that is fixed at the time of commitment to building or adding capacity. Evaluating the optimal product mix is of vital concern in any start-up processing environment. In this research the optimal product mix is evaluated by using a sophisticated evaluative tool known as PowerSim. This economic simulation software is used to model a start-up tomato processing plant in Ohio. The model evaluates the effects of various output, or tomato product mix, on plant profitability measured by ROI. Results indicate that an increase in plant profitability is expected when the tomato product mix consists of products that have a lower soluble solids concentration. The lower the soluble solids concentration of a tomato product, the less the processor will benefit from tomato varieties with high soluble solids. The processing operation achieves a RIO of 26.5 percent when the plant'Â’s product mix is 50 percent tomato paste (31 degrees brix) and 50 percent diced tomatoes. This product mix optimizes processor net income and realizes a plant return on equity of 50.6 percent.Agribusiness,

Coccidial Infection in Neonatal Swine

Coccidia have been implicated as another of the many pathogens responsible for scours in baby pigs. The clinical syndrome begins at about 5 days to 3 weeks of age and is similar to other enteritides of neonatal swine. The pigs begin to scour and do not grow well. In some cases, a mortality of up to 50% of those affected has been noted. Negative response to antibiotics normally employed in baby pig scours is often observed as another feature of the disease

Feasibility Of SigIlloidoscopic Screening For Bowel Cancer In A PriInary Care Setting

Abstract: Sigmoidoscopic screening for bowel cancer is controversial because of its debatable efficacy, lack of patient and physician acceptance ofthe procedure, and uncertainty about its practicality with the large numbers of patients in primary care settings. This study addressed patient acceptance and practicality. During an 18-month period, 75 percent of all patients aged 50 years and greater who were seen for health maintenance accepted sigmoidoscopy. The proceExperts' recommendations for health screening activities are often (but not always) based On clinical studies that show benefit to patients, but in the "real world" of the primary physician's office, other factors play a role in determining whether recommended activities are carried out. Other factors include: (I) the physician's interest in the recommended procedures, (2) the patient's acceptance of them, and (3) the ease with which they can be integrated into a busy practice setting. The net effect of these factors constitutes "feasibility" for the purpose of this report. Sigmoidoscopic screening for bowel cancer is a controversial procedure, and its feasibility has never been determined. Most physicians do not do it. lOne authority claims that most patients will not accept it. 2 Another believes it is not practical in the primary care setting. 3 Although sigmoidoscopic screening is recommended by the American Cancer SOciety,4 it is not recommended by other authorities who prefer screening for bowel cancer by means of fecal occult blood testing only.5" If the fecal occult blood test were a perfect test, there would be nO need to consider the merits of sigmoidoscopic screening because of the relative simplicity of the former. However, the fecal occult David L. Hahn, M.D. dure was integrated into office routines without disrupting other patient care. While compliance with fecal occult blood testing was high (88 percent), sensitivity of this test for neoplastic polyps within reach of the proctosigmoidoscope was low (11 percent). These results suggest that acceptance of sigmoidoscopy by patients seen in family physicians' offices could be greater than has been anticipated. (J Am Bd Fam PTact 1989; 2:25-9.) blood test is not a perfect test for cancer. There is a high false-positive rate: only 1 in 10 average-risk patients with a positive screening test will have cancer. 8 -10 There is a moderately high estimated false-negative rate, although final conclusions will have to await the results of ongoing prospective trials. 1 l,l2 Preliminary results suggest that the overall false-negative rate is about 30 percent. 8 Moreover, the false-negative rate for cancer in the distal colon (the area within reach of the sigmoidoscope) is higher. One review stated that the overall false-negative rate of the Hemoccult™ test for known cancer was between 33 to 50 percent and that results were more likely to be negative in left -sided lesions. lO Another study found a falsenegative rate of 45 percent for known rectal cancer. Sigmoidoscopic Screening 2

Environmental physiology and shelter engineering with special reference to domestic animals, LXXV : productive adaptability of Holstein cows to environmental heat. Part 1

September 1988.Bibliography : pages [12]-14

Environmental physiology and shelter engineering with special reference to domestic animals, LXXVI : short-term heat acclimation effects on hormonal profile of lactating cows. Part 2

September 1988.Bibliography : pages [12]-14

Secondary Outcomes of a Pilot Randomized Trial of Azithromycin Treatment for Asthma

OBJECTIVES: The respiratory pathogen Chlamydia pneumoniae (C. pneumoniae) produces acute and chronic lung infections and is associated with asthma. Evidence for effectiveness of antichlamydial antibiotics in asthma is limited. The primary objective of this pilot study was to investigate the feasibility of performing an asthma clinical trial in practice settings where most asthma is encountered and managed. The secondary objectives were to investigate (1) whether azithromycin treatment would affect any asthma outcomes and (2) whether C. pneumoniae serology would be related to outcomes. This report presents the secondary results. DESIGN: Randomized, placebo-controlled, blinded (participants, physicians, study personnel, data analysts), allocation-concealed parallel group clinical trial. SETTING: Community-based health-care settings located in four states and one Canadian province. PARTICIPANTS: Adults with stable, persistent asthma. INTERVENTIONS: Azithromycin (six weekly doses) or identical matching placebo, plus usual community care. OUTCOME MEASURES: Juniper Asthma Quality of Life Questionnaire (Juniper AQLQ), symptom, and medication changes from baseline (pretreatment) to 3 mo posttreatment (follow-up); C. pneumoniae IgG and IgA antibodies at baseline and follow-up. RESULTS: Juniper AQLQ improved by 0.25 (95% confidence interval; −0.3, 0.8) units, overall asthma symptoms improved by 0.68 (0.1, 1.3) units, and rescue inhaler use decreased by 0.59 (−0.5, 1.6) daily administrations in azithromycin-treated compared to placebo-treated participants. Baseline IgA antibodies were positively associated with worsening overall asthma symptoms at follow-up (p = 0.04), but IgG was not (p = 0.63). Overall asthma symptom improvement attributable to azithromycin was 28% in high IgA participants versus 12% in low IgA participants (p for interaction = 0.27). CONCLUSIONS: Azithromycin did not improve Juniper AQLQ but appeared to improve overall asthma symptoms. Larger community-based trials of antichlamydial antibiotics for asthma are warranted

UNLV New Horizons Band & UNLV Community Concert Band

Program listing performers and works performed

Gene discovery using massively parallel pyrosequencing to develop ESTs for the flesh fly Sarcophaga crassipalpis

<p>Abstract</p> <p>Background</p> <p>Flesh flies in the genus <it>Sarcophaga </it>are important models for investigating endocrinology, diapause, cold hardiness, reproduction, and immunity. Despite the prominence of <it>Sarcophaga </it>flesh flies as models for insect physiology and biochemistry, and in forensic studies, little genomic or transcriptomic data are available for members of this genus. We used massively parallel pyrosequencing on the Roche 454-FLX platform to produce a substantial EST dataset for the flesh fly <it>Sarcophaga crassipalpis</it>. To maximize sequence diversity, we pooled RNA extracted from whole bodies of all life stages and normalized the cDNA pool after reverse transcription.</p> <p>Results</p> <p>We obtained 207,110 ESTs with an average read length of 241 bp. These reads assembled into 20,995 contigs and 31,056 singletons. Using BLAST searches of the NR and NT databases we were able to identify 11,757 unique gene elements (E<0.0001) representing approximately 9,000 independent transcripts. Comparison of the distribution of <it>S. crassipalpis </it>unigenes among GO Biological Process functional groups with that of the <it>Drosophila melanogaster </it>transcriptome suggests that our ESTs are broadly representative of the flesh fly transcriptome. Insertion and deletion errors in 454 sequencing present a serious hurdle to comparative transcriptome analysis. Aided by a new approach to correcting for these errors, we performed a comparative analysis of genetic divergence across GO categories among <it>S. crassipalpis</it>, <it>D. melanogaster</it>, and <it>Anopheles gambiae</it>. The results suggest that non-synonymous substitutions occur at similar rates across categories, although genes related to response to stimuli may evolve slightly faster. In addition, we identified over 500 potential microsatellite loci and more than 12,000 SNPs among our ESTs.</p> <p>Conclusion</p> <p>Our data provides the first large-scale EST-project for flesh flies, a much-needed resource for exploring this model species. In addition, we identified a large number of potential microsatellite and SNP markers that could be used in population and systematic studies of <it>S. crassipalpis </it>and other flesh flies.</p

Chlamydia pneumoniae-Specific IgE Is Prevalent in Asthma and Is Associated with Disease Severity

Background: Several Chlamydia pneumoniae (Cp) biomarkers have been associated with asthma but Cp-specific IgE (Cp IgE) has not been investigated extensively. Our objective was to investigate Cp IgE in community adult asthma patients. Methods: (1) Prevalence of Cp IgE (measured by immunoblotting) and Cp DNA (by polymerase chain reaction) in peripheral blood, and biomarker associations with asthma severity. (2) Case-control studies of Cp IgE association with asthma using healthy blood donor (study 1) and non-asthmatic clinic patient (study 2) controls. Results: Of 66 asthma subjects (mean age 40.9 years, range 5–75, 59% male, 45% ever-smokers) 33 (50%) were Cp IgE positive and 16 (24%) were Cp DNA positive (P = 0.001 for association of Cp IgE and DNA). Cp IgE was detected in 21% of mild intermittent asthma v 79% of severe persistent asthma (test for trend over severity categories, P = 0.002). Cp IgE detection was significantly (P = 0.001) associated with asthma when compared to healthy blood donor controls but not when compared to clinic controls. Conclusions: Half of this sample of community asthma patients had detectable IgE against C. pneumoniae. Cp IgE was strongly and positively associated with asthma severity and with asthma when healthy blood donor controls were used. These results support the inclusion of Cp IgE as a biomarker in future studies of infectious contributions to asthma pathogenesis